BRIUMVI Post-Hoc Analysis Reveals Significant Efficacy in Highly Active MS Patients
TGTX is trading near its 52-week low of $25.28 (13% above the low).
Summary
TG Therapeutics announced the publication of a post hoc pooled analysis of its Phase 3 ULTIMATE I and II studies for BRIUMVI® in Neurology and Therapy. The data demonstrated statistically significant reductions in relapse rates (70.8% relative reduction) and MRI activity (95.6% reduction in Gd+ T1 lesions) in patients with highly active relapsing multiple sclerosis, along with a 4.8-fold higher likelihood of achieving NEDA-3. This publication reinforces the strong efficacy profile of BRIUMVI, particularly for a critical patient population at high risk for rapid disease progression. While BRIUMVI is already approved and a key revenue driver, this detailed scientific validation in a peer-reviewed journal provides further support for physician adoption and market penetration, building on the company's recently reported strong financial performance driven by BRIUMVI sales. Investors will watch for continued sales growth and market share expansion.
At the time of this announcement, TGTX was trading at $28.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $25.28 to $46.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.